Litchfield Hills initiates NextPlat stock with buy on healthcare growth

Litchfield Hills initiated NextPlat at Buy with an $11 price target versus a $6.35 share price, implying 73% upside. The note highlighted improving gross margins, better operating efficiency, and first-time profitability in the healthcare segment after restructuring and a CEO change. Q1 2026 results were mixed overall, with EPS of -$0.42 on $9.9 million of revenue, but operating losses narrowed materially and the stock screens at a steep discount to peers.

Analysis

NXPL is best viewed as a post-restructuring turnaround with leverage to two structurally favorable but very different markets: pharmacy services and satellite-enabled connectivity. The important second-order effect is that management is implicitly migrating the business mix away from low-quality revenue toward contracted, recurring services, which should compress volatility in EBITDA even if top-line growth remains lumpy. If that mix shift holds, the market is likely underestimating the multiple expansion potential because turnaround names usually re-rate on margin durability before revenue inflects.

The near-term winner is not just NXPL shareholders; pharmacy channel partners that can offload fulfillment and 340B complexity should gain operating leverage as regulatory and labor burdens rise. The losers are smaller independent operators and lower-scale pharmacy intermediaries that cannot match compliance infrastructure or working capital efficiency. The key second-order risk is that this is still a thinly traded small cap: any execution miss, delayed integration, or working-capital squeeze can overwhelm the fundamental progress and force a sharp de-rating before the market recognizes the margin improvement.

The contrarian angle is that the current setup may be more about survival-to-upside than a clean growth story. The market could be overpaying for the narrative if Q1 margin gains were partly mix-driven rather than sustainable operating leverage, especially with earnings still negative. That said, if the company can post two more quarters of sequential gross margin stability and operating loss reduction, the stock should trade less like a distressed retailer and more like a contracted services platform, which is where the rerating upside comes from.

Key Decisions for Investors

• Go long NXPL only on confirmation of 2Q/3Q sequential margin stability; base case 3-6 month holding period, with upside driven by multiple expansion rather than near-term EPS.
• Use a small starter position in NXPL and add on post-earnings strength; avoid full sizing upfront because the stock’s execution risk is high relative to its liquidity and negative earnings.
• If options are liquid, buy 3-6 month calls or call spreads on NXPL to express the turnaround with defined downside; target a 2:1 to 3:1 payoff if the market starts valuing the company on contracted service revenue.
• Pair NXPL long against a basket short of higher-cost independent pharmacy or low-quality retail healthcare names over the next 1-2 quarters; the trade benefits from channel consolidation and margin differentiation.
• If gross margin or operating loss trends reverse in the next quarter, cut quickly: this is a narrative-sensitive small cap where the re-rating can unwind in days, not months.